News

Caffeine Restores Levels of Protective Enzyme That Could Treat Dementia

Caffeine, along with 23 other compounds, increases levels of a neuroprotective enzyme called NMNAT2 (nicotinamide mononucleotide adenylyl transferase 2), with potential implications for the treatment of dementia, new research shows. The study, “Screening with an NMNAT2-MSD platform identifies small molecules that modulate NMNAT2 levels in cortical neurons,” appeared in…

Cerveau Technologies and Wisconsin Alzheimer’s Disease Research Center Sign Research Agreement

The University of Wisconsin-Madison’s Alzheimer’s Disease Research Center and Cerveau Technologies are partnering in research on the stages of Alzheimer’s and other neurodegenerative diseases. Wisconsin established the center in 2009 to focus on preclinical Alzheimer’s. Cerveau is a partnership between Enigma Biomedical Group and Sinotau Pharmaceutical Group. It was created to…

Genentech to Start Second Phase 3 Trial of Crenezumab as Alzheimer’s Treatment

Genentech will start a second Phase 3 clinical trial of crenezumab, an anti-Amyloid-beta antibody for treating Alzheimer’s disease that was developed by its partner, AC Immune. This trial, CREAD2, will complement the current randomized, double-blind, placebo-controlled, parallel group Phase 3 clinical trial (CREAD1, NCT02670083). CREAD1 is evaluating the effectiveness and…

Neurotrope Concludes Patient Dosing, Monitoring in Clinical Trial of Bryostatin-1 for Alzheimer’s

Neurotrope has finished dosing and monitoring patients in a Phase 2 clinical trial to evaluate Bryostatin-1, the company’s lead drug candidate for treatment of moderate to severe Alzheimer’s disease. The randomized, double-blind, placebo-controlled, Phase 2 clinical trial (NCT02431468) is assessing the safety, tolerability and efficacy of bryostatin-1 in 148 people…